SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford Medical Publications; 1987.
  • 2
    Wong JB. Cost-effectiveness of anti-tumor necrosis factor agents [review]. Clin Exp Rheumatol 2004; 22: S6570.
  • 3
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996.
  • 4
    Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003; 30: 8916.
  • 5
    Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measures in economic evaluation [review]. Health Technol Assess 1999; 3: iiv, 1–164.
  • 6
    Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982; 9: 78993.
  • 7
    Scott DL, Garrood T. Quality of life measures: use and abuse [review]. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 66387.
  • 8
    Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2004; 43: 6272.
  • 9
    Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004; 8: 191.
  • 10
    Torrance GW, Tugwell P, Amorosi S, Chartash E, Sengupta N. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. Rheumatology (Oxford) 2004; 43: 7128.
  • 11
    Tsuchiya A, Brazier J, McColl E, Parkin D. Deriving preference-based single indices from non-preference based condition-specific instruments: converting the AQLQ into EQ5D indices. URL: http://www.shef.ac.uk/content/1/c6/01/87/47/02_1FT.pdf.
  • 12
    Brazier JE, Kolotkin RL, Crosby RD, Williams GR. Estimating a preference-based single index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument from the SF-6D. Value Health 2004; 7: 4908.
  • 13
    Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 5372.
  • 14
    Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095108.
  • 15
    Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 27192.
  • 16
    Ware JE, Snow K, Kosinski M, Gandek B. SF-36 Health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
  • 17
    Zheng B. Summarizing the goodness of fit of generalized linear models for longitudinal data. Stat Med 2000; 19: 126575.
  • 18
    Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006; 26: 391400. URL: http://www.ohsu.edu/epc/mdm.
  • 19
    Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 55760.
  • 20
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, for the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 19329.
  • 21
    Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 67581.
  • 22
    Wolfe F, Michaud K. HAQ-based utilities and SF6D systematically overvalue quality of life (QOL) in RA patients with severe RA, pain and psychological distress [abstract]. Arthritis Rheum 2003; 48 Suppl 9: S399.
  • 23
    Marra CA, Esdaille JM, Guh D, Kopec JA, Brazier JE, Koehler BE, et al. A comparison of four indirect methods of assessing values in rheumatoid arthritis. Med Care 2004; 42: 112531.
  • 24
    National Institute for Clinical Excellence. Guide to the methods of technology appraisal. URL: http://www.nice.org.uk/download.aspx?0=201973.
  • 25
    Brazier J, Roberts J, Tsyuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004; 13: 87384.
  • 26
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, on behalf of the British Society for Rheumatology Biologics Register. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Arthritis Rheum 2006; 54: 178694.
  • 27
    Brennan A, Bansback N, Nixon RM, Madan J, Harrison M, Watson K, et al. Modeling the cost effectiveness of TNF alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologies Registry. Rheumatology (Oxford). In press.